电邮这篇文章 High- dose nitric oxide gas inhalation for HIV infection
- 作者: Pekshev A.V1, Vagapov A.B1, Sharapov N.A1, Vanin A.F2
-
隶属关系:
- N.E. Bauman Moscow State Technical University
- N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences
- 期: 卷 68, 编号 5 (2023)
- 页面: 1074-1080
- 栏目: Articles
- URL: https://bakhtiniada.ru/0006-3029/article/view/233485
- DOI: https://doi.org/10.31857/S0006302923050289
- EDN: https://elibrary.ru/NBAREQ
- ID: 233485
如何引用文章
全文:
详细
Therapeutic effect of high-dose nitric oxide gas inhalation (NO concentration was not less than than 1000 ppm) on two patients with HIV infection was shown. Inhaled NO therapy led to a rapid decrease in viral load to an undetectable level which was persistent even after analytical treatment interruption. It is suggested that HIV infection is controlled by nitrosonium (NO+) cations, the oxidized form of neutral NO molecules that enter the blood. Subsequent conversion of NO+ cations into nitrite anions due to a reaction with hydroxyl ions is inhibited by the binding of NO+ cations and chloride anions leading to the formation of nitrosyl chloride in the blood. Further entry of nitrosyl chloride into cells and tissues ensures NO+ transfer to them. Interaction between nitrosyl chloride and thiols requires the appearance of relevant S-nitrosothiols as NO donors in cells and tissues.
作者简介
A. Pekshev
N.E. Bauman Moscow State Technical UniversityMoscow, Russia
A. Vagapov
N.E. Bauman Moscow State Technical UniversityMoscow, Russia
N. Sharapov
N.E. Bauman Moscow State Technical UniversityMoscow, Russia
A. Vanin
N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences
Email: vanin.dnic@gmail.com
Moscow, Russia
参考
- М. Р. Бобкова, ВИЧ-инфекция и иммуносупрессии, 12 (1), 22 (2020).
- S. Kramer-Hammerle, I. Rothenaigner, H. Wolff, et al., Virus Res., 111, 194 (2005).
- T.-W. Chun, D. C. Nickle, J. S. Justement, et al., J. Infect. Dis., 197 (5), 714 (2008).
- S. Castro-Gonzalez, M. Colomer-Lluch, and R. Serra-Moreno, AIDS Res. Human Retroviruses, 34 (9), 739 (2018).
- C. S. Reiss and T. Komatsu, J. Virol., 72 (6), 4547 (1998).
- M. R. Garren, M. Ashcraft, Y. Qian, et al., Appl. Mater. Today, 22, 100887 (2021).
- F. Lisi, A. N. Zelikin, and R. Chandrawati, Adv. Sci., 8 (7), 2003895 (2021).
- F. Sodano, E. Gazzano, R. Fruttero, et al., Molecules, 27, 2337 (2022).
- T. Persichini, M. Colasanti, M. Fraziano, et al., Biochem. Biophys. Res.Commun., 254, 200 (1999).
- J. B. Mannick, J. S. Stamler, E. Teng, et al., J. Acquir. Immune Defic. Syndr., 22 (1), 1 (1999).
- T. Persichini, P. Ascenzi, V. Colizzi, et al., Int. J. Mol. Med., 4, 365 (1999).
- J. L. Jimenez, J. Gonzalez-Nicolas, S. Alvarez, et al., J. Virol., 75 (10), 4655 (2001).
- D. Torre, A. Pugliese, and F. Speranza, Lancet Infect. Dis., 2, 273 (2002).
- Е. В. Печёнкин, А. В. Коврижкин, А. В. Пекшев и др., Биофизика, 67 (6), 1251 (2022).
- А. Ф. Ванин, А. В. Пекшев, А. Б. Вагапов и др., Биофизика, 66 (1), 183 (2021).
- А. Ф. Ванин, А. В. Пекшев, Е. В. Печёнкин и др., Биофизика, 68 (1), 142 (2023).
- J. Z. Li, B. Etemad, H. Ahmed, et al., AIDS, 30 (3), 343 (2016).
- S. Khan, M. Kayahara, U. Joashi, et al., J. Cell Sci., 110, 2315 (1997).
- А. Ф. Ванин, А. А. Абрамов, А. Б. Вагапов и др., Биофизика, 68 (6) (2023) (в печати).
- А. В. Шиповалов, А. Ф. Ванин, О. В. Пьянков и др., Биофизика, 67 (5), 969 (2022).
- A. F. Vanin, V. A. Tronov, and R. R. Borodulin, Cell Biochem. Biophys., 79, 93 (2021).
- A. L. Kleschyov, S. Strand, S. Schmitt, et al., Free Rad. Biol. Med., 40, 1340 (2006).
补充文件
